WO2006136407A1 - Process for preparing amorphous rosuvastatin calcium free of impurities - Google Patents

Process for preparing amorphous rosuvastatin calcium free of impurities Download PDF

Info

Publication number
WO2006136407A1
WO2006136407A1 PCT/EP2006/006007 EP2006006007W WO2006136407A1 WO 2006136407 A1 WO2006136407 A1 WO 2006136407A1 EP 2006006007 W EP2006006007 W EP 2006006007W WO 2006136407 A1 WO2006136407 A1 WO 2006136407A1
Authority
WO
WIPO (PCT)
Prior art keywords
rosuvastatin
calcium
salt
process according
group
Prior art date
Application number
PCT/EP2006/006007
Other languages
French (fr)
Inventor
Marko Zlicar
Zdenko Casar
Original Assignee
Lek Pharmaceuticals D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals D.D. filed Critical Lek Pharmaceuticals D.D.
Priority to CA2612587A priority Critical patent/CA2612587C/en
Priority to AU2006261087A priority patent/AU2006261087B2/en
Priority to JP2008517413A priority patent/JP5146965B2/en
Priority to US11/922,532 priority patent/US9150518B2/en
Priority to EP06754501.2A priority patent/EP1912952B1/en
Priority to CN2006800228524A priority patent/CN101208307B/en
Publication of WO2006136407A1 publication Critical patent/WO2006136407A1/en
Priority to IL187483A priority patent/IL187483A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a process for the preparation of amorphous rosuvastatin calcium, substantially free of alkali metal impurities, via ammonium salts of rosuvastatin as intermediary compounds.
  • Rosuvastatin is generic name for (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-heptenoic acid administered in the therapy as its calcium salt as commercial drug, and illustrated in Formula 1 hereinafter, which compound is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase), useful in the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis.
  • HMG CoA reductase 3-hydroxy-3-methylglutaryl-coenzyme A reductase
  • WO 2005/023778 describes a process for the preparation of rosuvastatin calcium by conversion of C 1 to C 4 alkyl ester of rosuvastatin, preferably terf-butyl ester of rosuvastatin with a base, preferably sodium hydroxide, in the presence of a C 1 to C 4 alcohol, preferably ethanol, to a solution of rosuvastatin salt, e.g. its sodium salt and converted said salt into rosuvastatin calcium by adding a source of calcium to said solution.
  • a base preferably sodium hydroxide
  • a novel crystalline form of rosuvastatin calcium can be prepared by crystallization of amorphous form of rosuvastatin calcium from a mixture of: (i) water and acetonitrile in the ratio of 1 : 1 by volume; (ii) water and acetone in the ratio of 1 : 1 by volume; or water, methanol and methyl terf-butyl ether in the ratio of 1:1 :1 by volume, what is described in WO 2000/042024.
  • WO 01/60804 discloses certain novel amine salt with rosuvastatin, which may be prepared by addition of an appropriate amine or base to a solution of rosuvastatin acid in acetonitrile or ethyl acetate.
  • Certain novel amine salts of rosuvastatin may be used in the preparation of amorphous calcium salt of rosuvastatin, which process comprises sequential reaction of the crystalline methylammonium salt of rosuvastatin with sodium hydroxide, followed by a water soluble calcium salt, such as calcium chloride, under aqueous conditions.
  • amorphous calcium salt of rosuvastatin which process comprises sequential reaction of the crystalline methylammonium salt of rosuvastatin with sodium hydroxide, followed by a water soluble calcium salt, such as calcium chloride, under aqueous conditions.
  • An approach is disclosed in WO 2005/051921 where rosuvastatin calcium salt is purified by conversion into isopropylammonium or cyclohexylammonium salt and back to calcium salt.
  • a pure amorphous form of rosuvastatin calcium of Formula 1 having a purity of more than 99.5%, preferably a purity of more than 99.8%, more preferably a purity of more than 99.9% as determined by HPLC area percentage, and free from any traces of alkali metal impurities.
  • the present invention provides a process for producing pure amorphous calcium salt of rosuvastatin, substantially free of alkali metal impurities, e.g. sodium cation impurity, which comprises:
  • the starting ester may be methyl ester of rosuvastatin, preferably terf-butyl ester of rosuvastatin (tert-butyl rosuvastatin).
  • An organic nitrogen base is selected from the group consisting of guanidines, amidines, amines, quaternary ammonium hydroxides, unsubstituted or C 1 to C 6 alkyl substituted piperazines, morpholines, thiomorpholines, imidazolidines or adamantans.
  • Any aprotic solvent in step a) may be used, preferably tetrahydrofuran.
  • Any appropriate source of calcium may be used, preferably calcium chloride, calcium hydroxide, calcium acetate and calcium palmitate.
  • the process according to the invention may be performed in a solutions of an intermediary salts of rosuvastatin with organic nitrogen bases.
  • Said salts are novel compounds, e.g. amine salts of rosuvastatin, not described in the prior art.
  • rosuvastatin salts of an organic nitrogen bases may be isolated, optionally purified, e.g. by recrystallization, and used as intermediates in the preparation of the pure amorphous rosuvastatin calcium salt.
  • the desired pure amorphous rosuvastatin calcium salt is substantially free from any traces of alkali metal salt impurities, e.g. from sodium cation, containing in intermediary rosuvastatin sodium salt obtained according to prior art processes.
  • Amorphous rosuvastatin calcium prepared by the process according to the invention has at least 99.5% of chromatographic purity; moreover when using very pure starting C 1 to C 5 rosuvastatin ester more than 99.8% purity, even more, in some cases more than 99.9% of chromatographic purity of desired rosuvastatin calcium may be obtained.
  • chromatographic purity means purity as determined by area percentage HPLC ("High Pressure Liquid Chromatography").
  • the amorphous rosuvastatin calcium may be prepared by conversion of the novel intermediary ammonium salts of rosuvastatin with the source of calcium.
  • Intermediary ammonium salts of rosuvastatin may be obtained by contacting rosuvastatin free acid with an appropriate amine according to the procedure which comprises:
  • the water immiscible solvent used in above steps b) and d) is selected from the group consisting of C 2 to C 5 alkyl esters, e.g. acetate esters, preferably ethyl acetate (AcOEt), iso- propyl acetate (i-Pr acetate) and /so-butyl acetate, ethers, chlorinated hydrocarbons and cyclic hydrocarbons.
  • acetate esters e.g. acetate esters, preferably ethyl acetate (AcOEt), iso- propyl acetate (i-Pr acetate) and /so-butyl acetate, ethers, chlorinated hydrocarbons and cyclic hydrocarbons.
  • acid for acidifying aqueous solution of rosuvastatin alkali salt in step c) of above process e.g. hydrochloric acid or phosphoric acid may be used.
  • rosuvastatinic acid (rosuvastatin free acid) means (+)-7-[4-(4-fluorophenyl)-6- isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-6- heptenoic acid.
  • step a) for cleavage of starting rosuvastatin esters according to above procedure
  • purification and isolation of various isolable intermediary rosuvastatin salts with an appropriate amine may be performed after which the content of sodium cation impurity may be lowered, e.g. by washing the reaction mixture of step b) by water immiscible solvents, in the desired rosuvastatin calcium salt to less than 0.1 % of sodium by weight.
  • novel ammonium salts of rosuvastatin were prepared in well defined forms, preferably as terf-octylammonium salt of rosuvastatin, which may be isolated in highly pure crystalline form and may be valuable as analytical standard for HPLC and other analyses.
  • a pharmaceutical formulation comprising rosuvastatin calcium prepared according to above described process and a method of treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis, comprising the step of administering said pharmaceutical formulation to the mammal in need thereof.
  • An object of the present invention is to find a novel process for the preparation of pure amorphous rosuvastatin calcium, substantially free of sodium cation impurities or other alkali metal cation impurities and other impurities as well, which would avoid the use of alcohols, e.g. Ci to C 4 alcohols as a reaction medium and the use of alkali metal hydroxides, e.g. sodium hydroxide, thus eliminating O-alkyl rosuvastatin impurities (see Scheme 1), e.g.
  • the term “substantially free” means that the desired obtained amorphous rosuvastatin calcium is free of any traces of alkali metal impurities, e.g. sodium metal impurity.
  • the object of the present invention to find a novel process which would enable easy and simple preparation and optionally isolation of intermediary novel rosuvastatin salt with organic nitrogen bases, e.g. novel ammonium salts of rosuvastatin, in good quality, and which would enable simple and easy conversion of said novel intermediary compounds to desired commercial amorphous rosuvastatin calcium.
  • intermediary novel rosuvastatin salt with organic nitrogen bases e.g. novel ammonium salts of rosuvastatin
  • Residual sodium cation may be removed from rosuvastatin calcium by specific method, for instance the rosuvastatin calcium salt can be retreated by vigorous stirring in aqueous suspension, preferably by ultraturrax (Ultra-Turrax ® is brand name of IKA Werke GmbH & Co., Staufen, Germany for dispersion making device with high speed rotation unit).
  • ultraturrax Ultra-Turrax ® is brand name of IKA Werke GmbH & Co., Staufen, Germany for dispersion making device with high speed rotation unit.
  • the present invention provides the use of aqueous solution of organic nitrogen bases for cleavage of starting C 1 to C 5 alkyl ester of rosuvastatin or rosuvastatin lactone.
  • Strong organic nitrogen bases selected from the group consisting of guanidines and amidines can be a method of choice.
  • weak bases such as numerous amines if dissolved in water or in the mixtures of water and aprotic solvents, successfully cleft starting rosuvastatin esters if higher temperature is used.
  • by elevating temperature to 100 0 C desired product did not neither degrade in considerable extent nor lead to appearance of corresponding amides of rosuvastatin.
  • C 1 -C 5 alkyl esters of rosuvastatin or rosuvastatin lactone where alkyl denotes methyl, ethyl, n-proply, /so-propyl, n-butyl, /so-butyl, tert-butyl, amyl or te/f-amyl group, more preferably /ert-alkyl esters, most preferably te/f-butyl ester of rosuvastatin, are cleft in the solutions of organic nitrogen bases and water, optionally containing organic aprotic solvent, e.g. tetrahydrofuran.
  • organic aprotic solvent e.g. tetrahydrofuran
  • the organic nitrogen base used according to the process of the invention is selected from the group consisting of:
  • R 1 , R 2 , R3, R 4 and R 5 independently denotes a hydrogen atom, a straight chain or branched chain C 1 -C 6 alkyl group or cyclic C 1 -C 6 alkyl group or each pair of R 1 , R 2 , R 3 , R 4 and R 5 independently denotes a C 1 -C 6 alkylene group connection which forms a ring; b) amidines of the formula:
  • each of R 1 , R 2 , R3, and R 4 independently denotes a hydrogen atom, a straight chain or branched chain C 1 -C 6 alkyl group or cyclic C 1 -C 6 alkyl group or each pair of R 1 , R 2 , R 3 , and R 4 independently denotes a C 1 -C 6 alkylene group connection which forms a ring;
  • each of R 1 , R 2 and R 3 independently denotes a hydrogen atom, a straight chain or branched chain C 1 -C 6 alkyl group or cyclic C 1 -C 12 alkyl group, unsubstituted or substituted on one or more C-members of the alkyl chain with a radical selected from the group consisting of hydroxy, C 1 -C 6 alkoxy, amino, C 1 -C 6 alkylamino, di-C ⁇ Ce alkylamino, phenyl, pyridinyl, C 1 -C 6 alkylamino or each pair of R 1 , R 2 and R 3 independently denotes C 1 -C 6 alkylene connection which forms a ring;
  • each of R 1 , R 2 , R 3 and R 4 independently denotes a hydrogen atom, a straight chain or branched chain C 1 -C 6 alkyl group or cyclic C 1 -C 6 alkyl group or each pair of R 1 , R 2 , R 3 and R 4 independently denotes C 1 -C 6 alkylene group connection which forms a ring;
  • R denotes C 1 to C 5 alkyl group and R 1 , R 2 and R 3 denotes radicals as denoted in above formula of amines.
  • a preferred organic nitrogen base used from the guanidine group is N,N,N',N'-tetramethylguanidine, from the amidine group 1 ,5- diazabicyclo[4.3.0]non-5-ene (DBN) and 1. ⁇ -diazabicyclof ⁇ AOlundec-y-ene (DBU), from the amine group n-propylamine /so-propylamine, N-methylcyclohexylamine, dicyclohexylamine, N-methyl-iso-propylamine, N,N-di-iso-propylamine, tert-butylamine, tert-octylamine (2,4,4- trimethylpent-2-ylamine), sec-butylamine and diethylamine.
  • DBN diazabicyclo[4.3.0]non-5-ene
  • DBU 1. ⁇ -diazabicyclof ⁇ AOlundec-y-ene
  • the first aspect of the invention are starting Ci to C 5 esters of rosuvastatin or rosuvastatin lactone, hydrolysed with organic nitrogen bases in the presence of water, optionally containing aprotic organic solvent (water content is more than 50 % by volume, preferably more than 75 % by volume).
  • the hydrolysis is carried out at temperatures from 0° to 120 0 C.
  • strong organic nitrogen bases e.g. guanidines and amidines is preferred temperature from 20° to 70 0 C, more preferred from 40° to 60°.
  • weak bases e.g.
  • amines is the preferred temperature from 80° to 110 0 C, more preferred from 95° to 105 0 C, most preferred from 98° to 100 0 C.
  • the hydrolysis of starting rosuvastatin esters according to the invention by applying volatile amines is carried out in tightly closed vessels at increased pressures.
  • a novel intermediary ammonium salts of rosuvastatin may be isolated directly from the hydrolysis mixture by evaporation to dryness, optionally following by treatment with suitable solvent to induce solidification of the corresponding salt, which is further collected, e.g. by filtration.
  • suitable solvent e.g. water
  • the choice of a solvent for solidification depends on physico-chemical properties of particular salt and can be selected but not limited from nitriles, esters, ethers or hydrocarbons.
  • solid isopropylammonium salt of rosuvastatin from acetonitrile and N-methylcyclohexylammonium salt of rosuvastatin from tert-butyl methyl ether are isolated by this manner.
  • ammonium salts of rosuvastatin may be converted into rosuvastatin calcium salt without previous isolation of intermediary ammonium salt of rosuvastatin from the solution.
  • Aqueous solution of rosuvastatin salt with an appropriate amine obtained after hydrolysis step is optionally washed by water immiscible solvents and further converted with calcium source to precipitate the desired pure amorphous rosuvastatin calcium.
  • the water immiscible solvents are selected from the group consisting of esters, ethers, chlorinated hydrocarbons or cyclic hydrocarbons, preferably more user-friendly solvents, e.g. C 2 -C 5 acetate esters, e.g. ethyl acetate or cyclic hydrocarbons.
  • the source of calcium ion is selected from the group consisting of calcium halogenide, preferably calcium chloride, and another calcium source, e.g. calcium nitrate or calcium hydroxide, calcium salt of Ci-C 2O alkanoic acid, preferably calcium palmitate, calcium pivalate or calcium acetate.
  • the novel intermediary ammonium salts of rosuvastatin may be prepared from rosuvastatin free acid by the reaction with an appropriate amine.
  • the rosuvastatin free acid is prepared from a starting Ci to C 5 ester of rosuvastatin or rosuvastatin lactone by reacting it with a suitable base, e.g. sodium hydroxide, in the presence of an aprotic solvent, optionally diluted with water, and subsequent addition of an acid, e.g. phosphoric acid or hydrochloric acid, to the solution of rosuvastatin sodium salt, thus obtaining rosuvastatin free acid.
  • a suitable base e.g. sodium hydroxide
  • an aprotic solvent optionally diluted with water
  • an acid e.g. phosphoric acid or hydrochloric acid
  • the strong inorganic base used in the hydrolysis step may be sodium hydroxide or other alkali metal hydroxide, and the reaction is proceeded in the presence of water or in the presence of a mixture of aprotic solvents and water, such as a mixture of water and tetrahydrofuran, optionally under increased pressure.
  • the obtained solution of rosuvastatin alkaline salt is optionally washed by water immiscible solvents selected from the group consisting of esters, ethers, chlorinated hydrocarbons or cyclic hydrocarbons, preferably from more user-friendly solvents such as acetate esters, cyclic hydrocarbons or alkanes, more preferably from ethyl acetate.
  • the aqueous phase containing rosuvastatin alkaline salt is subsequently treated by a strong inorganic acid, preferably by phosphoric acid or hydrochloric acid.
  • Resulting rosuvastatinic acid (rosuvastatin free acid) is then extracted into water immiscible solvent and the obtained organic phase is converted to the ammonium salt of rosuvastatin by contacting with an appropriate amine.
  • an appropriate amine for the purpose of unification of water immiscible organic solvents, if said solvent is used to wash the reaction mixture, the same organic solvent may be used, for example an ester, preferably /so-propyl acetate, for the reaction with an amine.
  • the organic extract (above mentioned solution of rosuvastatinic acid in water immiscible solvent, e. g. isopropyl acetate) is treated with an appropriate amine to obtain the corresponding ammonium salt of rosuvastatin.
  • an antisolvent selected from other unpolar solvents, such as esters, ethers or hydrocarbons, optionally after concentration of the solution.
  • the extracting solvent can be completely removed to isolate the solid ammonium salt of rosuvastatin or if oily further treated with suitable solvent to induce solidification of the corresponding salt, which is finally collected, e.g. by filtration.
  • the solvent for the isolation of solid ammonium salt of rosuvastatin in all these alternatives strictly depends on solubility and physical properties of particular salt, but the preferred media are C 2 -C 5 acetate esters and ethers, most preferred /so-propyl acetate and terf-butyl methyl ether.
  • N-methylcyclohexylammonium salt (99.6% area by HPLC), cyclohexylammonium salt (99.71 % area); dicyclohexylammonim salt (99.82 % area); pyrrolidinium salt (99.71 % area); piperidinium salt (99.77% area); morpholinium salt (99.51 % area); 1-adamantylammonium salt (99.75% area); tert-octylammonium salt (99.87 % area).
  • Some of the isolated solid ammonium salts of rosuvastatin are good crystalline products, and can be isolated substantially pure.
  • a characteristic example is tert-octylammonium salt of rosuvastatin, which can be isolated in two different pseudopolymorphs and be because of its purity conveniently used as an analytical standard.
  • an anhydrous crystalline form is isolated having diffraction angles in X-ray powder analysis, shown in Table 3, that is the invention is embodied in crystalline tert-octylammonium salt of rosuvastatin having X-Ray powder diffraction pattern characteristic with peaks at 8.0, 15.0, 17.7, 18.4, 18.8, 20.3, and 23.4 ⁇ 0,2 ° 2 ⁇ and/or m.p. around 121 0 C.
  • a crystalline monohydrate is isolated having diffraction angles in X-ray powder analysis, shown in Table 4.
  • the invention is embodied in crystalline monohydrate of tert-octylammonium salt of rosuvastatin having X-Ray powder diffraction pattern with characteristic peaks at 8.6, 16.5, 18.6, 19.1 , and 19.7 ⁇ 0,2 °2Theta.
  • tert-octylammonium salt of rosuvastatin has stable defined structure, therefore is more suitable for use as an analytical standard than amorphous calcium salt with its hygroscopic properties and calcium assay variation.
  • the substance can be used as weighing standard compound in HPLC analyses of rosuvastatin.
  • the formed ammonium salts of rosuvastatin can be converted into rosuvastatin calcium salt by adding a source of calcium ions to said ammonium salt of rosuvastatin, preferably calcium acetate or calcium hydroxide, using water as a solvent.
  • Powder X-ray diffraction spectra of the sample was recorded on Siemens D-5000 with reflexion technique: CuKa radiation, range from 2° to 37° 2Theta, step 0.04° 2Theta, integration time 1 sec.
  • the accuracy in the difractograms is believed to be ⁇ 0.2, preferably ⁇ 0.1 2Theta.
  • tert-butylammonium salt of rosuvastatin is prepared with essentially the same yield:
  • the reactants and water as the solvent are stirred in the autoclave from 98° to 100 0 C for 3 hours.
  • the solution formed is then allowed to cool to room temperature, 150 ml of additional demineralized water and 20 ml tetrahydrofurane are added and some very little amount of solid impurities is filtered off.
  • the resulting solution is then washed with 2 x 200 ml methylcyclohexane and the aqueous phase is evaporated under reduced pressure at 70 0 C and 15 mbar to remove solvents and the N-methylcyclohexylamine. 50 ml toluene and 70 ml ethyl acetate are added and evaporated again to remove as much water as possible.
  • the reactants and solvents are stirred at 50 0 C for 2h.
  • the solution formed is then allowed to cool to room temperature and washed twice with 40 ml of methylcyclohexane.
  • the aqueous phase is partially evaporated to 25 g of total weight of the residue.
  • 0.1 g of charcoal is added to aqueous phase and resulting suspension is stirred for 30 minutes. Charcoal and some solid impurities are filtered off and filtrate is diluted to 30 ml of total volume.
  • cyclohexylammonium salt of rosuvastatin 0.45 g, 99.71% area by HPLC;
  • dicyclohexylammonim salt of rosuvastatin 0.35 g, 99.82% area;
  • piperidinium salt of rosuvastatin 0.28 g, 99.77% area;
  • morpholinium salt of rosuvastatin 0.30 g, 99.51% area;
  • 1-adamantylammonium salt of rosuvastatin 0.66 g, 99.75% area;
  • 16 ml of the filtrate is separated and treated by addition of 0.5 ml of cyclohexylamine in 8 ml of /so-propyl acetate during stirring and rosuvastatin cyclohexylammonium salt precipitate instantaneously as white solid. It is separated by filtration, precipitate is washed on the filter with 10 ml of /so-propyl acetate and dried on the filter yielding 1.34 g of the desired product (99.52% area, HPLC).
  • Rosuvastatin tert-butyl ester (27.0 g, 50.2 mmol) is dissolved in 225 ml of a mixture of tetrahydrofuran and water in the ratio of 4:1 by volume.
  • the clear solution is warmed to 30 0 C and 8.0 M NaOH (6.75 ml, 54.0 mmol) is added portionwise.
  • the reaction mixture is stirred at 30 0 C for 2 hours giving a clear yellow solution.
  • tetrahydrofuran is removed completely under the reduced pressure (20 mbar) at 40 0 C.
  • the remaining aqueous solution is diluted with water to 225 ml and washed with ethyl acetate (3*90 ml).
  • To a vigorously stirring solution of sodium rosuvastatinate is added dropwise HCI 37 % (4.2 ml, 50.2 mmol) at ambient temperature.
  • the obtained white emulsion of rosuvastatin free acid is extracted with ethyl acetate (150 ml). After separation from the organic layer aqueous phase is additionally extracted with ethyl acetate (2*50 ml). Organic layers are combined and washed with water (3*30 ml). Then ethyl acetate is removed under reduced pressure (20 mbar) at 40 °C. The residue is dissolved in a minimal amount of acetonitrile and the solvent is rapidly evaporated under reduced pressure (20 mbar) at 40 0 C to give 25.48 g of the solid residue. This solid is then dissolved in acetonitrile (100 ml) to give a clear solution.
  • tert-octylamine (6.83 g, 50.2 mmol) over 1 minute at ambient temperature.
  • white solid precipitates abundantly from the solution, which cause solidification of the mixture.
  • This solid is then treated with 75 ml of a mixture of hexane and acetonitrile in the ratio of 1:2 mixture by volume to give a dense suspension.
  • the white precipitate is filtered and dried in vacuum at 40 0 C to give 27.6 g of a white powder. This powder is suspended in hexane (100 ml) and vigorously stirred for 1 hour at ambient temperature.
  • Rosuvastatin terf-octylammonium salt (19.5 g) from Example 9 is dissolved in 429 ml of a mixture of acetonitrile and water in the ratio of 10 :1 by volume at ambient temperature. The solution is left to stand at 6 0 C for a few days. The white needles that crystallizes from the mixture are collected by filtration and dried in vacuum at 50 0 C to give 10.48 g (53.7 %) of crystalline rosuvastatin te/f-octylammonium monohydrate salt as white needles.
  • the reactants and the solvents are stirred 1.5 hours from 40° to 45°C hydrolysing starting rosuvastatin ester into its potassium salt.
  • the clear solution formed is washed twice with 50 ml methylcyclohexane followed by filtration to remove some little amount of solid impurities.
  • the filtrate is treated with 100 ml ethyl acetate and 4.3 ml of 85% phosphoric acid forming two layers.
  • the upper layer is separated and washed with 20 ml of water.
  • To the organic phase is then added 1.0 ml of 85% phosphoric acid and the reaction mixture is heated 5 minutes on the water-bath of the rotavapor at 50 0 C at atmospheric pressure. Then, the solvent is evaporated at reduced pressure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pure amorphous form of rosuvastatin calcium having purity of more than 99.5%, preferably a purity of more than 99.8%, more preferably a purity of more than 99.9% as determined by HPLC area percentage, and free from any traces of alkali metal impurities is disclosed. A process of preparing said pure amorphous form of rosuvastatin calcium is disclosed, which comprises hydrolysis of C1-C5 alkyl esters of rosuvastatin, preferably terf-butyl ester of rosuvastatin, with an organic nitrogen base, e.g. guanidines, amidines, amines and quaternary ammonium hydroxides, in the presence of water, optionally containing aprotic solvent, following the conversion of thus obtained rosuvastain salt with a source of calcium to desired rosuvastatin calcium, which is then isolated. An alternative process is disclosed, which comprises the conversion of numerous novel ammonium salts of rosuvastatin, preferably tert-octylammonium salt of rosuvastatin, with the source of calcium to desired commercial rosuvastatin calcium.. Rosuvastatin calcium is HMG CoA reductase, useful in the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis.

Description

Process for preparing amorphous rosuvastatin calcium free of impurities
Field of the invention
The present invention relates to a process for the preparation of amorphous rosuvastatin calcium, substantially free of alkali metal impurities, via ammonium salts of rosuvastatin as intermediary compounds.
Background of the invention
Rosuvastatin is generic name for (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-heptenoic acid administered in the therapy as its calcium salt as commercial drug, and illustrated in Formula 1 hereinafter, which compound is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase), useful in the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis. Rosuvastatin and the synthesis of rosuvastatin calcium was first described in patent EP-B-521 471 ; in the last two steps of the whole synthesis provided by hydrolysis of methyl ester of rosuvastatin (methyl rosuvastatin) in polar solvent, e.g. ethanol, in the presence of a base, e.g. sodium hydroxide, following by isolation of sodium salt of rosuvastatin and converting said sodium salt of rosuvastatin with a water soluble calcium salt under aqueous conditions to calcium salt of rosuvastatin. The process for the preparation of the intermediates described in EP-B-521 471 patent is incorporate herein by reference.
WO 2005/023778 describes a process for the preparation of rosuvastatin calcium by conversion of C1 to C4 alkyl ester of rosuvastatin, preferably terf-butyl ester of rosuvastatin with a base, preferably sodium hydroxide, in the presence of a C1 to C4 alcohol, preferably ethanol, to a solution of rosuvastatin salt, e.g. its sodium salt and converted said salt into rosuvastatin calcium by adding a source of calcium to said solution.
A novel crystalline form of rosuvastatin calcium can be prepared by crystallization of amorphous form of rosuvastatin calcium from a mixture of: (i) water and acetonitrile in the ratio of 1 : 1 by volume; (ii) water and acetone in the ratio of 1 : 1 by volume; or water, methanol and methyl terf-butyl ether in the ratio of 1:1 :1 by volume, what is described in WO 2000/042024. WO 01/60804 discloses certain novel amine salt with rosuvastatin, which may be prepared by addition of an appropriate amine or base to a solution of rosuvastatin acid in acetonitrile or ethyl acetate. Certain novel amine salts of rosuvastatin, preferably its crystalline methylammonium salt, may be used in the preparation of amorphous calcium salt of rosuvastatin, which process comprises sequential reaction of the crystalline methylammonium salt of rosuvastatin with sodium hydroxide, followed by a water soluble calcium salt, such as calcium chloride, under aqueous conditions. An approach is disclosed in WO 2005/051921 where rosuvastatin calcium salt is purified by conversion into isopropylammonium or cyclohexylammonium salt and back to calcium salt.
Figure imgf000003_0001
Formula 1
It is well known that alkali metal salts of organic acids are often hygroscopic what may cause problems at isolation. Indeed the isolation of sodium salt of rosuvastatin, which can be an intermediate in preparing rosuvastatin calcium salt, might be unrepeatable in yield and physical state what depends on the reaction conditions and evaporation of solvents, which is difficult to control. International publication WO 2005/23778 tried to avoid said problems without isolating rosuvastatin sodium salt by extraction of impurities from its aqueous solution into water immiscible solvent, but by using Ci to C4 alcohols as reaction medium a risk of conversion into specific impurities still existed. Namely, it is known that β-hydroxy acids in alcoholic alkali solution are submitted to dehydration what may lead after realkoxylation into special side products (see Scheme 1 , wherein R and R1 independently denotes Ci to C5 alkyl group), O-alkyl derivatives of rosuvastatin, e.g. O-ethyl rosuvastatin.
Therefore a need for an efficient process for preparing pure amorphous rosuvastatin calcium, without any significant amounts of side products and in having the exact stoichimetric content without other alkali metal cation, still exists. Summary of the invention
In a general aspect of the invention there is provided a pure amorphous form of rosuvastatin calcium of Formula 1 having a purity of more than 99.5%, preferably a purity of more than 99.8%, more preferably a purity of more than 99.9% as determined by HPLC area percentage, and free from any traces of alkali metal impurities.
In a first aspect the present invention provides a process for producing pure amorphous calcium salt of rosuvastatin, substantially free of alkali metal impurities, e.g. sodium cation impurity, which comprises:
a) hydrolysis of Ci to C5 alkyl esters of rosuvastatin or rosuvastatin lactone with an organic nitrogen base in the presence of water, optionally containing aprotic solvent, b) converting thus obtained rosuvastatin salt of an organic nitrogen base with a source of calcium to obtain rosuvastatin calcium, c) isolating the pure amorphous calcium salt of rosuvastatin.
The starting ester may be methyl ester of rosuvastatin, preferably terf-butyl ester of rosuvastatin (tert-butyl rosuvastatin).
An organic nitrogen base is selected from the group consisting of guanidines, amidines, amines, quaternary ammonium hydroxides, unsubstituted or C1 to C6 alkyl substituted piperazines, morpholines, thiomorpholines, imidazolidines or adamantans.
Any aprotic solvent in step a) may be used, preferably tetrahydrofuran.
Any appropriate source of calcium may be used, preferably calcium chloride, calcium hydroxide, calcium acetate and calcium palmitate.
The process according to the invention may be performed in a solutions of an intermediary salts of rosuvastatin with organic nitrogen bases. Said salts are novel compounds, e.g. amine salts of rosuvastatin, not described in the prior art.
In another aspect of the invention rosuvastatin salts of an organic nitrogen bases may be isolated, optionally purified, e.g. by recrystallization, and used as intermediates in the preparation of the pure amorphous rosuvastatin calcium salt. The desired pure amorphous rosuvastatin calcium salt is substantially free from any traces of alkali metal salt impurities, e.g. from sodium cation, containing in intermediary rosuvastatin sodium salt obtained according to prior art processes. Further is desired pure rosuvastatin calcium free of any O-alkyl derivatives of rosuvastatin, e.g. free of O-ethyl derivative of rosuvastatin, which may be obtained as side product according to prior art processes, performed in Ci to C4 alcoholic medium.
Amorphous rosuvastatin calcium prepared by the process according to the invention has at least 99.5% of chromatographic purity; moreover when using very pure starting C1 to C5 rosuvastatin ester more than 99.8% purity, even more, in some cases more than 99.9% of chromatographic purity of desired rosuvastatin calcium may be obtained.
The term "chromatographic purity" means purity as determined by area percentage HPLC ("High Pressure Liquid Chromatography").
In another aspect of the invention the amorphous rosuvastatin calcium may be prepared by conversion of the novel intermediary ammonium salts of rosuvastatin with the source of calcium. Intermediary ammonium salts of rosuvastatin may be obtained by contacting rosuvastatin free acid with an appropriate amine according to the procedure which comprises:
a) hydrolysis of C1 to C5 alkyl ester of rosuvastatin or rosuvastatin lactone with an alkali metal hydroxide in a mixture of an aprotic solvent and water, b) washing the reaction mixture with water immiscible solvent, c) acidifying aqueous solution of rosuvastatin alkali salt with an acid, d) extraction of the resulted aqueous solution of rosuvastatinic acid into a water immiscible organic solvent, e) adding an appropriate amine to the obtained extract containing rosuvastatinic acid to convert said rosuvastatinic acid into ammonium salt of rosuvastatin, f) converting ammonium salt of rosuvastatin with a source of calcium to obtain rosuvastatin calcium, g) isolation of amorphous rosuvastatin calcium.
The water immiscible solvent used in above steps b) and d) is selected from the group consisting of C2 to C5 alkyl esters, e.g. acetate esters, preferably ethyl acetate (AcOEt), iso- propyl acetate (i-Pr acetate) and /so-butyl acetate, ethers, chlorinated hydrocarbons and cyclic hydrocarbons.
As acid for acidifying aqueous solution of rosuvastatin alkali salt in step c) of above process e.g. hydrochloric acid or phosphoric acid may be used.
The term "rosuvastatinic acid" ("rosuvastatin free acid") means (+)-7-[4-(4-fluorophenyl)-6- isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-6- heptenoic acid.
By using sodium hydroxide in step a) for cleavage of starting rosuvastatin esters according to above procedure purification and isolation of various isolable intermediary rosuvastatin salts with an appropriate amine may be performed after which the content of sodium cation impurity may be lowered, e.g. by washing the reaction mixture of step b) by water immiscible solvents, in the desired rosuvastatin calcium salt to less than 0.1 % of sodium by weight.
Some of the novel ammonium salts of rosuvastatin were prepared in well defined forms, preferably as terf-octylammonium salt of rosuvastatin, which may be isolated in highly pure crystalline form and may be valuable as analytical standard for HPLC and other analyses.
The above described process of the first aspect of the invention by means of organic nitrogen bases cleavage of rosuvastatin C1 to C5 esters or lactone can be successfully applied for the preparation of other in the art known statins, preferably atorvastatin.
And in final aspect of the invention provides for a pharmaceutical formulation comprising rosuvastatin calcium prepared according to above described process and a method of treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis, comprising the step of administering said pharmaceutical formulation to the mammal in need thereof.
Detailed description of the invention
An object of the present invention is to find a novel process for the preparation of pure amorphous rosuvastatin calcium, substantially free of sodium cation impurities or other alkali metal cation impurities and other impurities as well, which would avoid the use of alcohols, e.g. Ci to C4 alcohols as a reaction medium and the use of alkali metal hydroxides, e.g. sodium hydroxide, thus eliminating O-alkyl rosuvastatin impurities (see Scheme 1), e.g. O- ethyl rosuvastatin derivative and obtaining rosuvastatin calcium free of any traces of sodium cation impurity or alkaline metal cation impurities, which may be present as impurities in rosuvastatin calcium, prepared according to the prior art processes.
Thus, the term "substantially free" means that the desired obtained amorphous rosuvastatin calcium is free of any traces of alkali metal impurities, e.g. sodium metal impurity.
Further is the object of the present invention to find a novel process which would enable easy and simple preparation and optionally isolation of intermediary novel rosuvastatin salt with organic nitrogen bases, e.g. novel ammonium salts of rosuvastatin, in good quality, and which would enable simple and easy conversion of said novel intermediary compounds to desired commercial amorphous rosuvastatin calcium.
We have unexpectedly and surprisingly found that above problem has been solved by hydrolysis of starting C1 to C5 alkyl esters of rosuvastatin (Formula 2) or rosuvastatin lactone (Formula 3), where instead of using C1 to C4 alcohols as protic solvent medium and strong inorganic alkali bases, e.g. sodium hydroxide, known in the prior art processes, hydrolysis take place in an aqueous solution of organic nitrogen bases. Namely, hydrolysis of starting C1 to C5 rosuvastatin esters in the presence of strong inorganic base, e.g. sodium hydroxide, according to the prior art processes, may result to incomplete conversion to desired rosuvastatin calcium. The consequence of incomplete conversion usually manifests in the presence of residual alkali metals, e.g. sodium cation, in the desired product. After using sodium hydroxide as a strong inorganic base, various amounts of residual sodium are found in the desired rosuvastatin calcium.
Figure imgf000007_0001
Formula 2 Formula 3 Residual sodium cation may be removed from rosuvastatin calcium by specific method, for instance the rosuvastatin calcium salt can be retreated by vigorous stirring in aqueous suspension, preferably by ultraturrax (Ultra-Turrax® is brand name of IKA Werke GmbH & Co., Staufen, Germany for dispersion making device with high speed rotation unit). Such methods eliminate sodium in a great extent, but none of the methods completely removes sodium from the desired rosuvastatin calcium.
The present invention provides the use of aqueous solution of organic nitrogen bases for cleavage of starting C1 to C5 alkyl ester of rosuvastatin or rosuvastatin lactone. Strong organic nitrogen bases selected from the group consisting of guanidines and amidines can be a method of choice. We have surprisingly found that also weak bases such as numerous amines if dissolved in water or in the mixtures of water and aprotic solvents, successfully cleft starting rosuvastatin esters if higher temperature is used. Moreover, we found out that by elevating temperature to 100 0C desired product did not neither degrade in considerable extent nor lead to appearance of corresponding amides of rosuvastatin.
According to the first aspect of the invention C1-C5 alkyl esters of rosuvastatin or rosuvastatin lactone, where alkyl denotes methyl, ethyl, n-proply, /so-propyl, n-butyl, /so-butyl, tert-butyl, amyl or te/f-amyl group, more preferably /ert-alkyl esters, most preferably te/f-butyl ester of rosuvastatin, are cleft in the solutions of organic nitrogen bases and water, optionally containing organic aprotic solvent, e.g. tetrahydrofuran.
The organic nitrogen base used according to the process of the invention is selected from the group consisting of:
a) guanidines of the formula:
R3 R4
wherein each of R1, R2, R3, R4 and R5 independently denotes a hydrogen atom, a straight chain or branched chain C1-C6 alkyl group or cyclic C1-C6 alkyl group or each pair of R1, R2, R3, R4 and R5 independently denotes a C1-C6 alkylene group connection which forms a ring; b) amidines of the formula:
Figure imgf000009_0001
wherein each of R1, R2, R3, and R4 independently denotes a hydrogen atom, a straight chain or branched chain C1-C6 alkyl group or cyclic C1-C6 alkyl group or each pair of R1, R2, R3, and R4 independently denotes a C1-C6 alkylene group connection which forms a ring;
c) amines of the formula:
R
2-N /Ri
R,
wherein each of R1, R2 and R3 independently denotes a hydrogen atom, a straight chain or branched chain C1-C6 alkyl group or cyclic C1-C12 alkyl group, unsubstituted or substituted on one or more C-members of the alkyl chain with a radical selected from the group consisting of hydroxy, C1-C6 alkoxy, amino, C1-C6 alkylamino, di-C^Ce alkylamino, phenyl, pyridinyl, C1-C6 alkylamino or each pair of R1, R2 and R3 independently denotes C1-C6 alkylene connection which forms a ring;
d) quaternary ammonium hydroxides of formula
NR1R2R3R4 +OH'
wherein each of R1, R2, R3 and R4 independently denotes a hydrogen atom, a straight chain or branched chain C1-C6 alkyl group or cyclic C1-C6 alkyl group or each pair of R1, R2, R3 and R4 independently denotes C1-C6 alkylene group connection which forms a ring;
e) unsubstituted or C1-C6 alkyl N-substituted piperazines, morpholines, thiomorpholines, imidazolidines or adamantans.
A process for preparing ammonium salts of rosuvastatin by hydrolysis of C1 to C5 alkyl esters of rosuvastatin or rosuvastatin lactone with amines of above formula in the presence of water is shown on the following Scheme 2.
Figure imgf000010_0001
Formula 2 (or Formula 3 - iactoπe)
Figure imgf000010_0002
Formula 4
Scheme 2
wherein in Formula 2 R denotes C1 to C5 alkyl group and R1, R2 and R3 denotes radicals as denoted in above formula of amines.
According to the process of the invention a preferred organic nitrogen base used from the guanidine group is N,N,N',N'-tetramethylguanidine, from the amidine group 1 ,5- diazabicyclo[4.3.0]non-5-ene (DBN) and 1.δ-diazabicyclofδAOlundec-y-ene (DBU), from the amine group n-propylamine /so-propylamine, N-methylcyclohexylamine, dicyclohexylamine, N-methyl-iso-propylamine, N,N-di-iso-propylamine, tert-butylamine, tert-octylamine (2,4,4- trimethylpent-2-ylamine), sec-butylamine and diethylamine. According to the first aspect of the invention are starting Ci to C5 esters of rosuvastatin or rosuvastatin lactone, hydrolysed with organic nitrogen bases in the presence of water, optionally containing aprotic organic solvent (water content is more than 50 % by volume, preferably more than 75 % by volume). The hydrolysis is carried out at temperatures from 0° to 120 0C. By said hydrolysis using strong organic nitrogen bases, e.g. guanidines and amidines is preferred temperature from 20° to 70 0C, more preferred from 40° to 60°. By said hydrolysis using weak bases, e.g. amines, is the preferred temperature from 80° to 110 0C, more preferred from 95° to 105 0C, most preferred from 98° to 100 0C. The hydrolysis of starting rosuvastatin esters according to the invention by applying volatile amines (boiling point bellow 120 0C) is carried out in tightly closed vessels at increased pressures.
In another aspect of the invention a novel intermediary ammonium salts of rosuvastatin may be isolated directly from the hydrolysis mixture by evaporation to dryness, optionally following by treatment with suitable solvent to induce solidification of the corresponding salt, which is further collected, e.g. by filtration. The choice of a solvent for solidification depends on physico-chemical properties of particular salt and can be selected but not limited from nitriles, esters, ethers or hydrocarbons. For example, solid isopropylammonium salt of rosuvastatin from acetonitrile and N-methylcyclohexylammonium salt of rosuvastatin from tert-butyl methyl ether are isolated by this manner.
In another aspect of the invention ammonium salts of rosuvastatin may be converted into rosuvastatin calcium salt without previous isolation of intermediary ammonium salt of rosuvastatin from the solution. Aqueous solution of rosuvastatin salt with an appropriate amine obtained after hydrolysis step is optionally washed by water immiscible solvents and further converted with calcium source to precipitate the desired pure amorphous rosuvastatin calcium.
The water immiscible solvents are selected from the group consisting of esters, ethers, chlorinated hydrocarbons or cyclic hydrocarbons, preferably more user-friendly solvents, e.g. C2-C5 acetate esters, e.g. ethyl acetate or cyclic hydrocarbons.
The source of calcium ion is selected from the group consisting of calcium halogenide, preferably calcium chloride, and another calcium source, e.g. calcium nitrate or calcium hydroxide, calcium salt of Ci-C2O alkanoic acid, preferably calcium palmitate, calcium pivalate or calcium acetate. In an another aspect of the invention the novel intermediary ammonium salts of rosuvastatin may be prepared from rosuvastatin free acid by the reaction with an appropriate amine.
The rosuvastatin free acid is prepared from a starting Ci to C5 ester of rosuvastatin or rosuvastatin lactone by reacting it with a suitable base, e.g. sodium hydroxide, in the presence of an aprotic solvent, optionally diluted with water, and subsequent addition of an acid, e.g. phosphoric acid or hydrochloric acid, to the solution of rosuvastatin sodium salt, thus obtaining rosuvastatin free acid.
The strong inorganic base used in the hydrolysis step may be sodium hydroxide or other alkali metal hydroxide, and the reaction is proceeded in the presence of water or in the presence of a mixture of aprotic solvents and water, such as a mixture of water and tetrahydrofuran, optionally under increased pressure. The obtained solution of rosuvastatin alkaline salt is optionally washed by water immiscible solvents selected from the group consisting of esters, ethers, chlorinated hydrocarbons or cyclic hydrocarbons, preferably from more user-friendly solvents such as acetate esters, cyclic hydrocarbons or alkanes, more preferably from ethyl acetate. The aqueous phase containing rosuvastatin alkaline salt is subsequently treated by a strong inorganic acid, preferably by phosphoric acid or hydrochloric acid.
Resulting rosuvastatinic acid (rosuvastatin free acid) is then extracted into water immiscible solvent and the obtained organic phase is converted to the ammonium salt of rosuvastatin by contacting with an appropriate amine. For the purpose of unification of water immiscible organic solvents, if said solvent is used to wash the reaction mixture, the same organic solvent may be used, for example an ester, preferably /so-propyl acetate, for the reaction with an amine.
In a further procedure the organic extract (above mentioned solution of rosuvastatinic acid in water immiscible solvent, e. g. isopropyl acetate) is treated with an appropriate amine to obtain the corresponding ammonium salt of rosuvastatin. Alternatively, if said salt remains dissolved it can be precipitated by an addition of an antisolvent selected from other unpolar solvents, such as esters, ethers or hydrocarbons, optionally after concentration of the solution. In another alternative, the extracting solvent can be completely removed to isolate the solid ammonium salt of rosuvastatin or if oily further treated with suitable solvent to induce solidification of the corresponding salt, which is finally collected, e.g. by filtration. The solvent for the isolation of solid ammonium salt of rosuvastatin in all these alternatives strictly depends on solubility and physical properties of particular salt, but the preferred media are C2-C5 acetate esters and ethers, most preferred /so-propyl acetate and terf-butyl methyl ether.
According to this described aspect of the invention the following solid ammonium salts of rosuvastatin in good quality may be isolated:
N-methylcyclohexylammonium salt (99.6% area by HPLC), cyclohexylammonium salt (99.71 % area); dicyclohexylammonim salt (99.82 % area); pyrrolidinium salt (99.71 % area); piperidinium salt (99.77% area); morpholinium salt (99.51 % area); 1-adamantylammonium salt (99.75% area); tert-octylammonium salt (99.87 % area).
Some of the isolated solid ammonium salts of rosuvastatin are good crystalline products, and can be isolated substantially pure. A characteristic example is tert-octylammonium salt of rosuvastatin, which can be isolated in two different pseudopolymorphs and be because of its purity conveniently used as an analytical standard.
From acetonitrile, optionally after washing with hexane an anhydrous crystalline form is isolated having diffraction angles in X-ray powder analysis, shown in Table 3, that is the invention is embodied in crystalline tert-octylammonium salt of rosuvastatin having X-Ray powder diffraction pattern characteristic with peaks at 8.0, 15.0, 17.7, 18.4, 18.8, 20.3, and 23.4 ±0,2 ° 2Θ and/or m.p. around 121 0C.
From a mixture of acetonitrile and water a crystalline monohydrate is isolated having diffraction angles in X-ray powder analysis, shown in Table 4. The invention is embodied in crystalline monohydrate of tert-octylammonium salt of rosuvastatin having X-Ray powder diffraction pattern with characteristic peaks at 8.6, 16.5, 18.6, 19.1 , and 19.7 ±0,2 °2Theta. Especially recrystallized anhydrous tert-octylammonium salt of rosuvastatin has stable defined structure, therefore is more suitable for use as an analytical standard than amorphous calcium salt with its hygroscopic properties and calcium assay variation. After determination of precise contain of rosuvastatin, for example by NMR or titration, the substance can be used as weighing standard compound in HPLC analyses of rosuvastatin. The formed ammonium salts of rosuvastatin can be converted into rosuvastatin calcium salt by adding a source of calcium ions to said ammonium salt of rosuvastatin, preferably calcium acetate or calcium hydroxide, using water as a solvent.
The following examples illustrate the invention, but do not limit it in any way:
Analytical data in examples were achieved by the following hardware:
Melting points were determined in Kofler hot stage microscope and differential dynamic calorimeter Mettler Toledo DSC822e
Powder X-ray diffraction spectra of the sample was recorded on Siemens D-5000 with reflexion technique: CuKa radiation, range from 2° to 37° 2Theta, step 0.04° 2Theta, integration time 1 sec. The accuracy in the difractograms is believed to be ± 0.2, preferably ± 0.1 2Theta.
Example 1
Hydrolysis of terf-butyl ester of rosuvastatin in aqueous solution of amines
7.5 g of terf-butyl ester of rosuvastatin 38 ml of demineralized water 2 to 5 equivalents of amine
The reactants and water as the solvent are stirred in the autoclave from 98° to 1000C for 1 to 4 hours. The reaction mixture is sampled and analyzed by HPLC ("High Pressure Liquid Chromatography") to find out the completion of reaction. Results are shown in Table 1.
Figure imgf000015_0001
Table 1
Example 2
Hydrolysis of rosuvastatin lactone in aqueous solution of N-methylcyclohexylamine
0.5 g of rosuvastatin lactone
0.5 ml of N-methylcyclohexylamine
3.0 ml of demineralized water
The reactants and the solvent are stirred 1 hour at 900C forming clear solution and analysed as described in Example 1. HPLC analysis shows total consumption of the starting lactone.
Example 3
Hydrolysis of terf-butyl ester of rosuvastatin in a solution of strong organic nitrogen bases
The solution of terf-butyl ester of rosuvastatin in a mixture of a base, tetrahydrofuran and water in the ratio of 1:6:15 by volume is stirred at 50°C for few hours. The reaction mixture is sampled and analysed by HPLC to find out the completion of reaction. Results are shown in Table 2.
Figure imgf000016_0001
Table 2
Example 4
Preparation of /so-propylammonium salt of rosuvastatin
7.2 g of terf-butyl ester of rosuvastatin 35 ml of demineralized water 4.5 ml of /so-propylamine
The reactants and water as the solvent are stirred in the autoclave from 98° to 100°C for 2 hours. The solution formed is then allowed to cool to room temperature and some very little amount of solid impurities is filtered off. Filtrate is washed twice with 20 ml of /so-propyl acetate and the aqueous phase is then evaporated under reduced pressure at 700C and 15 mbar to remove solvents and /so-propylamine. 7.15 g of white solid residue of rosuvastatin /so-propylammonium salt is collected.
This amount is added to 70 ml acetonitrile and the suspension formed is heated under reflux (800C) for 1h. Then, it is left for 2h at O0C. Subsequently, the product is separated by filtration. Yield: 6.7 g of white crystals of the pure product (>99.9% area, HPLC)
1H-NMR: (CD3OD): 1.29 (12H,d, J=7Hz), 1.48 - 1.56 (1H,m), 1.62 - 1.72 (1H,m), 2.25 (1H,dd, J1=MHz, J2=7,.6Hz), 2.34 (1 H,dd, J1=MHz, J2=4.9Hz), 3.39 (1H,h, J=7Hz), 3.51 (1H,h, J=7Hz), 3.52 (3H,s), 3.53 (3H,s), 3.92 - 4.00 (1H,m), 4.33 - 4.40 (1H,m), 5.57 (1H,dd, J!=16Hz, J2=6Hz), 6.62 (1H.dd, J1=^Hz, J2=1.2Hz), 7.14 - 7.22 (1H,m), 7.69 - 7.75 (1H,m). Analogously, tert-butylammonium salt of rosuvastatin is prepared with essentially the same yield:
1H-NMR: (CD3OD): 1.29.(6H,d, J=7Hz), 1.35.(9H,s), 1.48 - 1.56.(1 H,m), 1.62 - 1.72.(1H,m), 2.25.(1 H,dd, J,=15Hz, J2=7.6Hz), 2.34.(1H,dd, J1=ISHz, J2=4.9Hz), 3.51.(1H,h, J=7Hz), 3.52.(3H1S), 3.53.(3H,s), 3.92 - 4.00.(1H,m), 4.33 - 4.40.(1 H,m), 5.57.(1 H,dd, J1=^Hz, J2=6Hz), 6.62.(1H,dd, J,=16Hz, J2=I .2Hz), 7.14 - 7.22.(1 H,m), 7.69 - 7.75.(1H,m).
Example 5
Preparation of N-methylcyclohexylammonium salt of rosuvastatin
50 g of tert-butyl ester of rosuvastatin 225 ml of demineralized water 25 ml of N-methylcyclohexylamine
The reactants and water as the solvent are stirred in the autoclave from 98° to 1000C for 3 hours. The solution formed is then allowed to cool to room temperature, 150 ml of additional demineralized water and 20 ml tetrahydrofurane are added and some very little amount of solid impurities is filtered off. The resulting solution is then washed with 2 x 200 ml methylcyclohexane and the aqueous phase is evaporated under reduced pressure at 700C and 15 mbar to remove solvents and the N-methylcyclohexylamine. 50 ml toluene and 70 ml ethyl acetate are added and evaporated again to remove as much water as possible. To the oily residue 250 ml tert-butyl methyl ether is added and the mixture is digested forming white suspension. After cooling it at 0°C for 12 hours, the suspension is filtered and washed with 60 ml terf-butyl methyl ether and dried on the filter. Yield: 50.8 g of white solid of N- methylcyclohexylammonium salt of rosuvastatin.
Example 6
Preparation of N-methylcyclohexylammonium salt of rosuvastatin from N,N,N',N'- tetramethylguanidine salt of rosuvastatin
5.0 g of tert-butyl ester of rosuvastatin 1.4 ml of N.N.N'.N'-tetramethylguanidine 25 ml of demineralized water 10 ml of tetrahydrofuran
The reactants and solvents are stirred at 500C for 2h. The solution formed is then allowed to cool to room temperature and washed twice with 40 ml of methylcyclohexane. The aqueous phase is partially evaporated to 25 g of total weight of the residue. 0.1 g of charcoal is added to aqueous phase and resulting suspension is stirred for 30 minutes. Charcoal and some solid impurities are filtered off and filtrate is diluted to 30 ml of total volume.
To 30 ml of the obtained solution 40 ml /ert-butyl methyl ether is added 1.3 ml of 85% phosphoric acid in 5 ml of water and the resulting mixture is stirred for 15 minutes. A two- phase system is formed. Organic layer is separated and washed with 5 ml of water and dried with 5 g of anhydrous magnesium sulphate for 2 h. Magnesuim sulphate is then separated by filtration.
To filtrate is then added 1.5 ml N-methylcyclohexylamine and the reaction mixture is stirred for 2 hours at room temperature and then it is left resting at 00C for 12 hours. White precipitate of N-methylcyclohexylammonium salt of rosuvastatin is filtered off and washed with 5 ml of terf-butyl methyl ether and dried on the filter for 2 hours. Yield: 4.04 g of the title product (99.6% area, HPLC)
1H-NMR: (CD3OD): 1.10 - 1.45 (12H,m), 1.31 (d, J=7Hz), 1.48 - 1.56 (1H,m), 1.62 - 1.72 (1H,m), 1.82 - 1.90 (2H,m), 2.03 - 2.10 (2H,m), 2.25 (1H,dd, J1=UHz, J2=7.6Hz), 2,34 (1 H.dd, J1=UHz, J2=4.9Hz), 2,62 (3H,s), 2.85 - 2.97 (1H,m), 3.51 (1H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 - 3.97 (1 H,m), 4.33 - 4.40 (1H,m), 5.56 (1 H,dd, J1=IeHz, J2=6Hz), 6.62 (1H,dd, J1=^Hz, J2=I .2Hz), 7.14 - 7.22 (1H,m), 7,69 - 7,75 (1 H,m).
Example 7
General procedure for preparing isolated ammonium salts of rosuvastatin
5 g of terf-butyl ester of rosuvastatin 1.75 ml of 8 M NaOH 25 ml of demineralized water 10 ml of tetrahydrofuran The reactants and the solvents are stirred from 50° to 55°C for 1 hour. The solution formed is then allowed to cool to room temperature and washed with 50 ml methylcyclohexane yielding 33 ml of aqueous solution of sodium salt of rosuvastatin.
To 33 ml of sodium rosuvastatinate solution prepared in the above described experiment is added 1.3 ml 85% phosphoric acid, previously dissolved in 5 ml of water. Reaction mixture is extracted with 40 ml of /so-butyl acetate. Organic layer is separated off and dried with 5 g of anhydrous magnesium sulphate. Drying agent is filtered off and washed with 10 ml /so-butyl acetate obtaining 52 ml of filtrate containing rosuvastatinic acid, which is divided into smaller portions for preparing various ammonium salts.
To 5 ml of the obtained solution 1.5 equivalents of appropriate amine and 5 ml tert-butyl methyl ether are added. Rosuvastatin substituted ammonium salt is filtered off and dried on filter. The following solid salts are prepared:
cyclohexylammonium salt of rosuvastatin: 0.45 g, 99.71% area by HPLC;
1H-NMR: (CD3OD): 1.10 - 1.45 (12H,m), 1.31 (6H,d, J=7Hz), 1.48 - 1.56 (1H,m), 1.62 - 1.72 (1 H,m), 1.80 - 1.87 (2H,m), 1.97 - 2.03 (2H,m), 2.25 (1H,dd, J1=MHz, J2=7.6Hz), 2.34 (1H,dd, J1=MHz1 J2=4.9Hz), 2.98 - 3.09 (1 H,m), 3.51 (1H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 - 3.97 (1H,m), 4.33 - 4.40 (1H,m), 5.56 (1 H,dd, J1=^Hz, J2=6Hz), 6.62 (1H,dd, J1=^Hz, J2=1.2Hz), 7.14 - 7.22 (2H,m), 7.69 - 7.75 (1H,m);
dicyclohexylammonim salt of rosuvastatin: 0.35 g, 99.82% area;
1H-NMR: (CD3OD): 1.12 - 1.76 (20H,m), 1.29 (d, J=7Hz), 1.48 - 1.56 (1H,m), 1.62 - 1.72 (1H,m), 1.83 - 1.92 (4H,m), 2.01 - 2.09(4H,m), 2.25 (1H,dd, J1=HHz, J2=7,6Hz), 2.34 (1H,dd, J1=MHz, J2=4.9Hz), 3.07 - 3.17 (2H,m), 3.51 (1H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 - 3.97 (1H,m), 4.33 - 4.40 (1H,m), 5.56 (1H,dd, J1=IeHz, J2=6Hz), 6.62 (1H,dd, J,=16Hz, J2=1.2Hz), 7.14 - 7.22 (2H,m), 7.69 - 7,75 (2H,m);
pyrrolidinium salt of rosuvastatin: 0.28 g, 99.71% area,
1H-NMR: (CD3OD): 1.29 (6H,d, J=7Hz), 1.48 - 1.56 (1H,m), 1.62 - 1.72 (1H,m), 1.96 - 2.01 (4H,m), 2.25 (1H,dd, J1=MHz, J2=7,6Hz), 2.34 (1H,dd, J1=MHz, J2=4,9Hz), 3.20 - 3.25 (4H,m), 3,51 (1H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 - 3.97 (1 H,m), 4.33 - 4.40 (1 H,m), 5.56 (1H,dd, J1=IeHz, J2=6Hz), 6.62 (1 H,dd, J1=IeHz, J2=1 ,2Hz), 7.14 - 7.22 (2H,m), 7.69 - 7.75 (2H,m);
piperidinium salt of rosuvastatin: 0.28 g, 99.77% area;
1H-NMR: (CD3OD): 1.29 (6H,d, J=7Hz), 1.48 - 1.56 (1H,m), 1.62 - 1.81 (7H,m), 2.25 (1 H,dd, J1=MHz, J2=7.6Hz), 2,34 (1 H,dd, J1=MHz, J2=4,9Hz), 3.09 - 3.13 (4H,m), 3.51 (1 H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 - 3.97 (1H,m), 4.33 - 4.40 (1 H,m), 5.56 (1 H,dd, J1=IeHz, J2=6Hz), 6.62 (1H,dd, J1=^Hz, J2=1.2Hz), 7.14 - 7,22 (1H,m), 7.69 - 7.75 (2H,m);
morpholinium salt of rosuvastatin: 0.30 g, 99.51% area;
1H-NMR: (CD3OD): 1.29 (6H,d, J=7Hz), 1.49 - 1.57 (1 H,m), 1.62 - 1.72 (1H,m), 2.25 (1 H,dd, J1=MHz, J2=7.6Hz), 2.34 (1 H,dd, J1=HHz, J2=4.9Hz), 3.12 - 3.16 (4H,m), 3.51 (1 H,h, J=7Hz), 3.52 (3H,s), 3.53 (3H,s), 3.81 - 3.,85 (4H,m), 3.92 - 4.00 (1H,m), 4.33 - 4.40 (1H,m), 5.57 (1H,dd, J1=IeHz, J2=6Hz), 6.62 (1H,dd, J1=IeHz, J2=1.2Hz), 7.14 - 7.22 (2H,m), 7.69 - 7.75 (1H,m);
1-adamantylammonium salt of rosuvastatin: 0.66 g, 99.75% area;
1H-NMR: (CD3OD): 1.29 (6H,d, J=7Hz), 1.48 - 1.56 (1H,m), 1.62 - 1.85 (16H,m), 2.15 (3H,s (broad)), 2.25 (1 H,dd, J1=HHz, J2=7,6Hz), 2.34 (1H,dd, J1=UHz, J2=4.9Hz), 3.51 (1 H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 - 3.97 (1H,m), 4.33 - 4.40 (1 H,m), 5.56 (1H,dd, J1=IeHz, J2=6Hz), 6.62 (1 H,dd, J1=^Hz, J2=1.2Hz), 7.14 - 7.22 (2H,m), 7.69 - 7.75 (1 H,m).
Example 8
Preparation of N-cyclohexylammonium salt of rosuvastatin
1O g tert-butyl ester of rosuvastatin
3.5 ml 8 M NaOH
50 ml demineralized water
20 ml tetrahydrofuran The reactants and the solvents are stirred from 50° to 55°C for 1 hour. The solution formed is then allowed to cool to room temperature and washed with 100 ml methylcyclohexane yielding 66 ml of aqueous solution of sodium rosuvastatinate.
To 33 ml of the obtained solution is added 1.3 ml 85% phosphoric acid in 5 ml demineralized water. Rosuvastatinic acid is extracted with 40 ml /so-propyl acetate. 4.7 g of anhydrous magnesium sulphate and 0.5 g charcoal is added to organic phase and suspension is stirred for 45 min. Magnesium sulphate and charcoal are filtered off yielding 41 ml of filtrate.
16 ml of the filtrate is separated and treated by addition of 0.5 ml of cyclohexylamine in 8 ml of /so-propyl acetate during stirring and rosuvastatin cyclohexylammonium salt precipitate instantaneously as white solid. It is separated by filtration, precipitate is washed on the filter with 10 ml of /so-propyl acetate and dried on the filter yielding 1.34 g of the desired product (99.52% area, HPLC).
Example 9
Preparation of crystalline rosuvastatin te/f-octylammonium salt
Rosuvastatin tert-butyl ester (27.0 g, 50.2 mmol) is dissolved in 225 ml of a mixture of tetrahydrofuran and water in the ratio of 4:1 by volume. The clear solution is warmed to 30 0C and 8.0 M NaOH (6.75 ml, 54.0 mmol) is added portionwise. The reaction mixture is stirred at 30 0C for 2 hours giving a clear yellow solution. Then tetrahydrofuran is removed completely under the reduced pressure (20 mbar) at 40 0C. The remaining aqueous solution is diluted with water to 225 ml and washed with ethyl acetate (3*90 ml). To a vigorously stirring solution of sodium rosuvastatinate is added dropwise HCI 37 % (4.2 ml, 50.2 mmol) at ambient temperature.
The obtained white emulsion of rosuvastatin free acid is extracted with ethyl acetate (150 ml). After separation from the organic layer aqueous phase is additionally extracted with ethyl acetate (2*50 ml). Organic layers are combined and washed with water (3*30 ml). Then ethyl acetate is removed under reduced pressure (20 mbar) at 40 °C. The residue is dissolved in a minimal amount of acetonitrile and the solvent is rapidly evaporated under reduced pressure (20 mbar) at 40 0C to give 25.48 g of the solid residue. This solid is then dissolved in acetonitrile (100 ml) to give a clear solution. To a vigorously stirring solution of rosuvastatin free acid is added dropwise tert-octylamine (6.83 g, 50.2 mmol) over 1 minute at ambient temperature. In less then 10 minutes white solid precipitates abundantly from the solution, which cause solidification of the mixture. This solid is then treated with 75 ml of a mixture of hexane and acetonitrile in the ratio of 1:2 mixture by volume to give a dense suspension. The white precipitate is filtered and dried in vacuum at 40 0C to give 27.6 g of a white powder. This powder is suspended in hexane (100 ml) and vigorously stirred for 1 hour at ambient temperature. The undissolved precipitate is collected by filtration, washed with hexane (50 ml) and dried in vacuum at 40 0C to give 27.4 g (89.4 %) of rosuvastatin tert- octylammonium salt as white crystalline powder.
Melting point: 121 0C (DSC1 onset)
X-Ray powder analysis - diffraction angles (2 theta) - Figure 1 :
Angle (° 2Θ) Relative intensity ( %)
7.13 14.45
8.00 39.04
9.18 19.37
10.40 19.55
12.47 39.04
14.42 33.65
14.97 42.00
15.48 28.38
15.78 34.00
15.95 33.65
17.68 100.00
18.44 83.35
18.77 39.87
19.68 33.53
20.27 44.55
23.35 45.85
24.24 30.27
29.31 28.79
Table 3
Example 10
Preparation of crystalline rosuvastatin te/f-octylammonium monohydrate salt
Rosuvastatin terf-octylammonium salt (19.5 g) from Example 9 is dissolved in 429 ml of a mixture of acetonitrile and water in the ratio of 10 :1 by volume at ambient temperature. The solution is left to stand at 6 0C for a few days. The white needles that crystallizes from the mixture are collected by filtration and dried in vacuum at 50 0C to give 10.48 g (53.7 %) of crystalline rosuvastatin te/f-octylammonium monohydrate salt as white needles.
Melting point: 129 0C (DSC, onset), dehydration 85° to 1050C
X-Ray powder analysis - diffraction angles (2 theta) - Figure 2:
Angle (° 2Θ) Relative intensity ( %)
4.68 19.36
8.63 51.97
9.36 21.74
10.15 21.58
10.42 10.28
14.10 34.45
14.37 29.04
16.54 41.32
16.98 34.51
18.59 100.00
19.14 65.60
19.72 81.83
27.31 20.01
Table 4
Example 11
Preparation of rosuvastatin calcium from tert-butyl ester of rosuvastatin via DBU salt
1.0 g of tert-butyl ester of rosuvastatin
0.32 ml of 1 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU)
5 ml of demineralized water
2 ml of tetrahydrofuran
The reactants and the solvents are stirred at 500C for 2 h. The solution formed is then allowed to cool to room temperature and 2 ml demineralized water is added. Reaction mixture is washed twice with 10 ml methylcyclohexane. Combined organic phases are washed with 2 ml demineralized water. Combined aqueous phases are partially evaporated reducing original weight for 3.7 g. To remaining solution 0.25 ml of 4M calcium chloride is added during stirring and cooling on ice-bath for 15 minutes. White precipitate of rosuvastatin calcium is filtered off and washed with 1 ml demineralized water. 0.64 g of the desired amorphous product is collected after drying for 12 hours at room temperature in vacuum desiccator.
Example 12
Preparation of rosuvastatin calcium from rosuvastatin lactone Wa DBU salt
0.5 g rosuvastatin lactone 0.20 ml DBU 3.0 ml water
The reactants and the solvent are stirred 1 hour at 900C forming clear solution. HPLC shows total consumation of the starting lactone.
Then, 0.16 g of calcium acetate monohydrate in 2 ml of water is added and the suspension formed is treated with ultraturrax at 15000 rpm for 5 minutes. The white precipitate of rosuvastatin calcium is separated by filtration. Yield: 0.42 g of the amorphous product.
Example 13
Preparation of rosuvastatin calcium from /so-propylammonium salt of rosuvastatin
7.5 g of terf-butyl ester of rosuvastatin
37 ml of water
3.5 ml of /so-propylamine calcium hydroxide
The reactants and the solvent are stirred in the autoclave from 95° to 1000C for 2 hours. Reaction mixture is allowed to cool to room temperature and subsequently 20 ml of demi- water is added. Reaction mixture is washed twice with 37 ml methylcyclohexane. To aqueous phase 0.08 g charcoal is added and the resulting suspension is stirred for 45 minutes. Charcoal and some little amounts of solid impurities are filtered off. Resulting clear solution (containing rosuvastatin /so-propylammonium salt) is evaporated at reduced pressure to oily residue, which is diluted with water to 70 ml of total volume. To the obtained solution of rosuvastatin /so-propylammonium salt is added 2.0 g of moist calcium hydroxide paste (cca 50% content) and resulting suspension is stirred for 1 h at room temperature under nitrogen and for additional 15 min on ice-bath. White precipitate is then filtered off and washed with 8 ml of ice-cold demineralized water. The product is dried under vaccum at 600C for 3 hours. Yield: 6.15 g of amorphous rosuvastatin calcium.
Example 14
Preparation of rosuvastatin calcium from /so-propylammonium salt of rosuvastatin
2.0 g of rosuvastatin /so-propylammonium salt 13 ml of demineralized water 2.0 ml of 1 M calcium acetate
The reactants and the solvent are digested with ultraturrax for 2 minutes at 10000 rpm under nitrogen and then stirred 10 minutes with magnetic bar at 10°C. White precipitate is filtered off and washed with 2 ml demineralized water. It is dried 1 hour on the filter and 2 hours from 50° to 600C at 10 mbars. Yield: 1.67 g of amorphous rosuvastatin calcium (>99.8% area, HPLC, <0.1% sodium calculated on the content of calcium)
Example 15
Preparation of rosuvastatin calcium from N-methylcyclohexylammonium salt of rosuvastatin
1.0 g rosuvastatin N-methylcyclohexylammonium salt 0.48 g of calcium palmitate 5.0 ml /so-butyl acetate
The reactants and the solvent are stirred 5 minutes at 800C. Gradually, 6 ml of methylcyclohexane is added within 5 minutes at 800C. The reaction mixture is then stirred for 20 minutes at room temperature. Resulting precipitate is separated by filtration and washed on filter with 5 ml methylcyclohexane. 0.40 g of amorphous rosuvastatin calcium is collected (99.26% area, HPLC)
Example 16
Preparation of rosuvastatin lactone 20.0 g rosuvastatin tert-butyl ester
6.5 ml 8M KOH
40 ml tetrahydrofuran
100 ml demineralized water
The reactants and the solvents are stirred 1.5 hours from 40° to 45°C hydrolysing starting rosuvastatin ester into its potassium salt. The clear solution formed is washed twice with 50 ml methylcyclohexane followed by filtration to remove some little amount of solid impurities. Then, the filtrate is treated with 100 ml ethyl acetate and 4.3 ml of 85% phosphoric acid forming two layers. The upper layer is separated and washed with 20 ml of water. To the organic phase is then added 1.0 ml of 85% phosphoric acid and the reaction mixture is heated 5 minutes on the water-bath of the rotavapor at 500C at atmospheric pressure. Then, the solvent is evaporated at reduced pressure. To the syrupy residue another 100 ml of ethyl acetate is added and the process of heating, evaporation and adding ethyl acetate is repeated three times. At last, the ethyl acetate solution of rosuvastatin lacton is washed with 20 ml of 5% solution of sodium bicarbonate and twice with 30 ml water. The solvent is evaporated at reduced pressure giving 17.0 g of syrupy residue, which crystallized on standing (91% area by HPLC).
By consecutive treatment with ultraturrax at 15000 rpm in 80 ml of terf-butyl methyl ether, filtration and recrystallization from /so-propyl acetate / diisopropyl ether the purity is enhanced to 95% area.

Claims

Claims
1. A process for producing pure amorphous rosuvastatin calcium which comprises:
a) hydrolysis of C1 to C5 alkyl esters of rosuvastatin or rosuvastatin lactone with an organic nitrogen base in the presence of water, optionally containing an aprotic solvent, b) converting thus obtained rosuvastatin salt of organic nitrogen base with a source of calcium to obtain rosuvastatin calcium, c) isolating pure amorphous rosuvastatin calcium.
2. A process according to claim 1 , wherein C1 to C5 alkyl ester of rosuvastatin is terf-butyl rosuvastatin.
3. A process according to claim 1 , wherein the organic nitrogen base is selected from the group consisting of:
a) guanidines of the formula:
Figure imgf000027_0001
wherein each of R1, R2, R3, R4 and R5 independently denotes a hydrogen atom, a straight chain or branched chain Ci-C6 alkyl group or cyclic C1-C6 alkyl group or each pair of R1, R2, R3, R4 and R5 independently denotes a C1- C6 alkylene group connection which forms a ring,
b) amidines of the formula:
Figure imgf000027_0002
wherein each of R1, R2, R3, R4 and R5 independently denotes a hydrogen atom, a straight chain or branched chain C1-C6 alkyl group or cyclic Ci-C6 alkyl group or each pair of R1, R2, R3, and R4 independently denotes a C1-C6 alkylene group connection which forms a ring;
b) amines of the formula
Figure imgf000028_0001
wherein each of R1, R2 and R3 independently denotes a hydrogen atom, a straight chain or branched chain C1-C6 alkyl group or cyclic C1-C12 alkyl group, unsubstituted or substituted on one or more C-members of the alkyl chain with a radical selected from the group consisting of hydroxy, C1-C6 alkoxy, amino, C1-C6 alkylamino, di-d-C6 alkylamino, phenyl, pyridinyl, C1-C6 alkylamino or each pair of R1, R2 and R3 independently denotes C1-C6 alkylene group connection which forms a ring;
d) quaternary ammonium hydroxides of formula:
NR1R2R3R4 +OH-
wherein each of R1, R2, R3 and R4 independently denotes a hydrogen atom or chained, branched or cyclic C1-C6 alkyl group or each pair of R1, R2, R3 and R4 independently denotes C1-C6 alkylene connection which forms a ring;
e) unsubstituted or C1-C6 alkyl N-substituted piperazines, morpholines, thiomorpholines, imidazolidines or adamantans.
4. A process according to claims 1 and 3 a), wherein the organic nitrogen base is N.N.N'N'-tetramethylguanidine
5. A process according to claims 1 and 3 b), wherein the organic nitrogen base is selected from the group consisting of 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) and 1 ,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
6. A process according to claims 1 and 3 c), wherein the organic nitrogen base is selected from the group consisting of /so-propylamine, sec-butylamine, tert- butylamine, diethylamine, N.N-diisopropylamine, N-methyl-isopropylamine, N- methylcyclohexylamine.
7. A process according to claim 1 , wherein the source of calcium is selected from the group consisting of calcium chloride, calcium nitrate, calcium hydroxide and calcium salt of C1-C2O alkanoic acid.
8. A process according to claims 1 and 7, wherein the calcium salt of C1-C20 alkanoic acid is selected from the group consisting of calcium palmitate, calcium pivalate and calcium acetate.
9. A process according to claim 1 , wherein the aprotic solvent is tetrahydrofuran.
10. A process according to claims 1 and 3 c), wherein the molar ratio of the amine and C1 to C5 alkyl ester of rosuvastatin or rosuvastatin lactone is from 1 to 30.
11. A process according to claims 1 and 3c), wherein the molar ratio of the amine and C1 to C5 ester of rosuvastatin is from 2 to 5.
12. Rosuvastatin calcium substantially free of alkali metal impurities.
13. Rosuvastatin calcium according to claim 12, substantially free of sodium metal impurity.
14. A process for preparing amorphous rosuvastatin calcium, which comprises:
a) hydrolysis of C1 to C5 alkyl ester of rosuvastatin or rosuvastatin lactone with an alkali metal hydroxide in a mixture of an aprotic solvent and water, b) washing the reaction mixture with water immiscible organic solvent, c) acidifying the aqueous solution of rosuvastatin alkali salt with an acid, d) extraction of the resulted aqueous solution of rosuvastatinic acid into a water immiscible organic solvent, e) adding an appropriate amine to the obtained extract contaning rosuvastatinic acid to convert said rosuvastatinic acid into ammonium salt of rosuvastatin, f) converting ammonium salt of rosuvastatin with a source of calcium to obtain rosuvastatin calcium, g) isolation of amorphous rosuvastatin calcium.
15. A process according to claim 14, wherein Ci to C5 alkyl ester of rosuvastatin is te/t-butyl rosuvastatin.
16. A process according to claim 14, wherein an alkali metal hydroxide is sodium hydroxide.
17. A process according to claim 14, wherein the aprotic solvent is tetrahydrofuran.
18. A process according to claim 14, wherein water immiscible organic solvent is selected from the group consisting of C2-C5 alkyl acetate.
19. A process according to claims 14 and 18, wherein C2 to C5 alkyl acetate is selected from the group consisting of ethyl acetate, /so-propyl acetate and /so-butyl acetate.
20. A process according to claim 14, wherein the water immiscible organic solvent is methylcyclohexane.
21. A process according to claim 14, wherein the acid is selected from the group consisting of phosphoric acid and hydrochloric acid.
22. A process for preparing ammonium salt of rosuvastatin according to claim 14, which comprises contacting rosuvastatinic acid with an appropriate amine.
23. A process for preparing ammonium salt of rosuvastatin according to claims 14 and 22, wherein the appropriate amine is selected from the group consisting of pyrrolidine, piperidine, morpholine, 1-adamantane, cyclohexylamine, N.N-dicyclohexylamine, iso- propylamine, tert-octylamine.
24. A process according to claim 14, wherein the source of calcium is selected from the group consisting of calcium chloride, calcium nitrate, calcium hydroxide, calcium salt of C1 to C2O alkanoic acid.
25. A process according to claims 14 and 24, wherein the calcium salt of C1 to C2o alkanoic acid is selected from the group consisting of calcium palmitate, calcium pivalate and calcium acetate.
26. A process according to claim 14, wherein the solution of ammonium salt of rosuvastatin in a water immiscible solvent is converted with a source of calcium to rosuvastatin calcium.
27. A process according to claim 14, wherein ammonium salt of rosuvastatin is isolated from the extract and further converted with a source of calcium to rosuvastatin calcium.
28. A process according to claims 14 and 27, wherein isolated ammonium salt of rosuvastatin is purified by recrystallization before conversion to rosuvastatin calcium.
29. Solid pyrrolidinium salt of rosuvastatin.
30. Solid piperidinium salt of rosuvastatin.
31. Solid morpholinium salt of rosuvastatin.
32. Solid 1-adamantylammonium salt of rosuvastatin
33. Solid N.N-dicyclohexylammonim salt of rosuvastatin.
34. Solid N-methylcyclohexylammonim salt of rosuvastatin.
35. Solid tert-octylammonium salt of rosuvastatin.
36. Crystalline tert-octylammonium salt of rosuvastatin.
37. Crystalline tert-octylammonium salt of rosuvastatin according to previous claim having X-Ray powder diffraction pattern with characteristic peaks at 8.0, 15.0, 17.7, 18.4, 18.8, 20.3, and 23.4 ±0,2 ° 2Θ)
38. Crystalline tert-octylammonium salt of rosuvastatin according to previous claim having X-Ray powder diffraction pattern with peaks:
Angle (° 2Θ) Relative intensity ( %)
7.13 14.45
8.00 39.04
9.18 19.37
10.40 19.55
12.47 39.04
14.42 33.65
14.97 42.00
15.48 28.38
15.78 34.00
15.95 33.65
17.68 100.00
18.44 83.35
18.77 39.87
19.68 33.53
20.27 44.55
23.35 45.85
24.24 30.27
29.31 28.79
39. Crystalline tert-octylammonium salt of rosuvastatin as monohydrate.
40. Crystalline tert-octylammonium salt of rosuvastatin as monohydrate according to previous claim having X-Ray powder diffraction pattern with characteristic peaks at 8.6, 16.5, 18.6, 19.1, and 19.7 ±0,2 ° 2Θ)
41. Crystalline tert-octylammonium salt of rosuvastatin as monohydrate according to previous claim having X-ray powder diffraction pattern with peaks:
Angle (° 2Θ) Relative intensity ( %)
4.68 19.36
8.63 51.97
9.36 21.74
10.15 21.58
10.42 10.28
14.10 34.45
14.37 29.04
16.54 41.32
16.98 34.51
18.59 100.00
19.14 65.60
19.72 81.83
27.31 20.01
42. Use of crystalline terf-octylammonium salt of rosuvastatin as analytical standard.
43. Rosuvastatin calcium prepared according to claim 14, containing less than 0.1% of alkali metal cation impurities.
44. A pharmaceutical formulation for administration to a mammal in need of a reduction in blood cholesterol level comprising rosuvastatin calcium prepared according to any of previous claims.
45. A method of treating a mammal in need of a reduction in blood cholesterol level comprising the step of administering the pharmaceutical formulation of claim 44 to the mammal in need thereof.
PCT/EP2006/006007 2005-06-24 2006-06-22 Process for preparing amorphous rosuvastatin calcium free of impurities WO2006136407A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2612587A CA2612587C (en) 2005-06-24 2006-06-22 Process for preparing amorphous rosuvastatin calcium free of impurities
AU2006261087A AU2006261087B2 (en) 2005-06-24 2006-06-22 Process for preparing amorphous rosuvastatin calcium free of impurities
JP2008517413A JP5146965B2 (en) 2005-06-24 2006-06-22 Method for preparing amorphous rosuvastatin calcium free of impurities
US11/922,532 US9150518B2 (en) 2005-06-24 2006-06-22 Process for preparing amorphous rosuvastatin calcium of impurities
EP06754501.2A EP1912952B1 (en) 2005-06-24 2006-06-22 Process for preparing amorphous rosuvastatin calcium free of impurities
CN2006800228524A CN101208307B (en) 2005-06-24 2006-06-22 Process for preparing amorphous rosuvastatin calcium free of impurities
IL187483A IL187483A (en) 2005-06-24 2007-11-19 Process for producing pure amorphous rosuvastatin calcium, crystalline tert-octyl ammonium salt of rosuvastatin and use thereof in hplc analysis of rosuvastatin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200500188 2005-06-24
SIP200500188 2005-06-24

Publications (1)

Publication Number Publication Date
WO2006136407A1 true WO2006136407A1 (en) 2006-12-28

Family

ID=37038337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006007 WO2006136407A1 (en) 2005-06-24 2006-06-22 Process for preparing amorphous rosuvastatin calcium free of impurities

Country Status (8)

Country Link
US (1) US9150518B2 (en)
EP (2) EP2508514B1 (en)
JP (1) JP5146965B2 (en)
CN (2) CN102807530B (en)
AU (1) AU2006261087B2 (en)
CA (1) CA2612587C (en)
IL (1) IL187483A (en)
WO (1) WO2006136407A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244844B2 (en) 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
WO2007125547A3 (en) * 2006-05-03 2008-04-03 Reddy Manne Satyanarayana Novel process for statins and its pharmaceutically acceptable salts thereof
US7396927B2 (en) 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
US7612203B2 (en) 2005-02-22 2009-11-03 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
WO2009156173A1 (en) 2008-06-27 2009-12-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising a statin
WO2010081861A1 (en) * 2009-01-14 2010-07-22 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of rosuvastatin
WO2010082072A1 (en) 2009-01-15 2010-07-22 Egis Gyógyszergyár Process for the preparation of rosuvastatin salts
US7777034B2 (en) 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
US7868169B2 (en) 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
US7884226B2 (en) 2007-07-12 2011-02-08 Teva Pharmaceutical Industries, Ltd. Purification of rosuvatatin intermediate by thin film evaporation and chemical method
WO2012073055A1 (en) 2010-11-29 2012-06-07 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Method for the preparation of high-purity pharmaceutical intermediates
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
WO2012073054A2 (en) 2010-11-29 2012-06-07 Egis Gyógyszergyár Nyilvánosan Múködó Részvény-Társaság Method for preparing rosuvastatin salts
US20130018065A1 (en) * 2009-12-16 2013-01-17 Lek Pharmaceuticals D.D. Processes for the preparation of key intermediate for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
WO2014154856A1 (en) * 2013-03-29 2014-10-02 Dsm Sinochem Pharmaceuticals Netherlands B.V. Amine salts of pravastatin and rosuvastatin
WO2014154857A1 (en) * 2013-03-29 2014-10-02 Dsm Sinochem Pharmaceuticals Netherlands B.V. Amine salts of pitavastatin and rosuvastatin
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
CZ306425B6 (en) * 2012-05-16 2017-01-18 Zentiva, K.S. A method of preparing pitavastatin calcium salt

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318933B2 (en) * 2006-10-31 2012-11-27 Aurobindo Pharma Ltd Process for preparing rosuvastatin calcium
WO2008096257A1 (en) 2007-02-08 2008-08-14 Aurobindo Pharma Limited An improved process for preparation of rosuvastatin calcium
WO2012176218A1 (en) * 2011-06-24 2012-12-27 Ind-Swift Laboratories Limited Process for preparing rosuvastatin calcium through novel amine salt
RO129060B1 (en) 2013-04-25 2014-11-28 Antibiotice S.A. Stable pharmaceutical composition with amorphous rosuvastatin calcium
CN113461619A (en) * 2014-02-06 2021-10-01 株式会社Api Production method of rosuvastatin calcium and intermediate thereof
KR101660249B1 (en) * 2014-07-11 2016-09-28 주식회사 경보제약 Method for the preparation of high purity Rosuvastatin Calcium salt
KR102060318B1 (en) * 2019-03-26 2019-12-30 (주)헥사파마텍 Novel intermediate, processes for preparing the same, and processes for preparing rosuvastatin calcium salt using the same

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521471A1 (en) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives as HMG-CoA reductase inhibitors
WO2001060804A1 (en) * 2000-02-15 2001-08-23 Astrazeneca Ab Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2003097614A2 (en) * 2002-05-21 2003-11-27 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
WO2004014872A1 (en) * 2002-08-13 2004-02-19 Astrazeneca Uk Limited Process for preparing the calcium salt of rosuvastatin
WO2004052867A1 (en) * 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
WO2005023778A2 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
WO2005040134A1 (en) * 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
WO2005042522A1 (en) * 2003-10-24 2005-05-12 Astrazeneca Uk Limited Process for the manufacture of the calcium salt of rosuvatatin (e)-7-`4- (4-fluorophenyl) -6-isopropyl-2-`methyl (methylsulfonyl) amino ! pyrimidin -5-yl ! (3r, 5s) -3, 5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
WO2005077916A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
WO2005092867A2 (en) * 2004-03-26 2005-10-06 Avecia Pharmaceuticals Limited Process and intermediate compounds useful in the preparation of statins, particularly rosuvastatin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312914A (en) * 1987-02-17 1994-05-17 Ciba-Geigy Corp Process for the manufacture of 4-acetoxy-3-hydroxyethyl-azetidinone
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
US7199144B2 (en) * 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
CZ200486A3 (en) * 2004-01-16 2005-08-17 Zentiva, A.S. Process for preparing hemicalcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid
ES2564807T5 (en) * 2005-06-24 2019-02-26 Lek Pharmaceuticals Process for the preparation of pure amorphous calcium rosuvastatin

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521471A1 (en) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives as HMG-CoA reductase inhibitors
WO2001060804A1 (en) * 2000-02-15 2001-08-23 Astrazeneca Ab Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2003097614A2 (en) * 2002-05-21 2003-11-27 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
WO2004014872A1 (en) * 2002-08-13 2004-02-19 Astrazeneca Uk Limited Process for preparing the calcium salt of rosuvastatin
WO2004052867A1 (en) * 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
WO2005023778A2 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
WO2005040134A1 (en) * 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
WO2005042522A1 (en) * 2003-10-24 2005-05-12 Astrazeneca Uk Limited Process for the manufacture of the calcium salt of rosuvatatin (e)-7-`4- (4-fluorophenyl) -6-isopropyl-2-`methyl (methylsulfonyl) amino ! pyrimidin -5-yl ! (3r, 5s) -3, 5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
WO2005054207A1 (en) * 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
WO2005077916A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
WO2005092867A2 (en) * 2004-03-26 2005-10-06 Avecia Pharmaceuticals Limited Process and intermediate compounds useful in the preparation of statins, particularly rosuvastatin

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396927B2 (en) 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
US7777034B2 (en) 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
US7741482B2 (en) 2003-12-02 2010-06-22 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7692010B2 (en) 2003-12-02 2010-04-06 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7692009B2 (en) 2003-12-02 2010-04-06 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7692008B2 (en) 2003-12-02 2010-04-06 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7244844B2 (en) 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US8487097B2 (en) 2003-12-02 2013-07-16 Teva Pharmacedutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7612203B2 (en) 2005-02-22 2009-11-03 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US8063211B2 (en) 2005-02-22 2011-11-22 Teva Pharmaceutical Industries, Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US7868169B2 (en) 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
WO2007125547A3 (en) * 2006-05-03 2008-04-03 Reddy Manne Satyanarayana Novel process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
US7884226B2 (en) 2007-07-12 2011-02-08 Teva Pharmaceutical Industries, Ltd. Purification of rosuvatatin intermediate by thin film evaporation and chemical method
WO2009156173A1 (en) 2008-06-27 2009-12-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising a statin
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
EA019995B1 (en) * 2009-01-14 2014-07-30 Крка, Товарна Здравил, Д.Д., Ново Место Rosuvastatin salt, process for the preparation thereof and process for the preparation of pharmaceutically acceptable rosuvastatin salt
WO2010081861A1 (en) * 2009-01-14 2010-07-22 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of rosuvastatin
EA021942B1 (en) * 2009-01-15 2015-10-30 Эгиш Дьёдьсердьяр Зрт. Process for the preparation of rosuvastatin salts
WO2010082072A1 (en) 2009-01-15 2010-07-22 Egis Gyógyszergyár Process for the preparation of rosuvastatin salts
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
US20130018065A1 (en) * 2009-12-16 2013-01-17 Lek Pharmaceuticals D.D. Processes for the preparation of key intermediate for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
US9067895B2 (en) * 2009-12-16 2015-06-30 Lek Pharmaceuticals D.D. Processes for the preparation of key intermediate for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
EA023769B1 (en) * 2010-11-29 2016-07-29 Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг Method for preparing rosuvastatin salts
WO2012073054A2 (en) 2010-11-29 2012-06-07 Egis Gyógyszergyár Nyilvánosan Múködó Részvény-Társaság Method for preparing rosuvastatin salts
JP2013543884A (en) * 2010-11-29 2013-12-09 エギシュ ヂョヂセルヂャール ニルヴァーノサン ミケデ レースヴェーニタールササーグ Manufacturing method for high-purity pharmaceutical intermediates
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
WO2012073054A3 (en) * 2010-11-29 2012-11-15 Egis Gyógyszergyár Nyilvánosan Múködó Részvény-Társaság Method for preparing rosuvastatin salts
EA029079B1 (en) * 2010-11-29 2018-02-28 Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг Method for the preparation of high-purity pharmaceutical intermediates
US9040696B2 (en) 2010-11-29 2015-05-26 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Method for preparing rosuvastatin salts
US9133132B2 (en) 2010-11-29 2015-09-15 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Method for the preparation of high-purity pharmaceutical intermediates
WO2012073055A1 (en) 2010-11-29 2012-06-07 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Method for the preparation of high-purity pharmaceutical intermediates
CZ306425B6 (en) * 2012-05-16 2017-01-18 Zentiva, K.S. A method of preparing pitavastatin calcium salt
WO2014154856A1 (en) * 2013-03-29 2014-10-02 Dsm Sinochem Pharmaceuticals Netherlands B.V. Amine salts of pravastatin and rosuvastatin
CN105377817A (en) * 2013-03-29 2016-03-02 中化帝斯曼制药有限公司荷兰公司 Amine salts of pitavastatin and rosuvastatin
CN105189458A (en) * 2013-03-29 2015-12-23 中化帝斯曼制药有限公司荷兰公司 Amine salts of pitavastatin and rosuvastatin
US9630906B2 (en) 2013-03-29 2017-04-25 Dsm Sinochem Pharmaceuticals Netherlands B.V. Amine salts of pitavastatin and rosuvastatin
US9676729B2 (en) 2013-03-29 2017-06-13 Dsm Sinochem Pharmaceuticals Netherlands B.V. Amine salts of pitavastatin and rosuvastatin
WO2014154857A1 (en) * 2013-03-29 2014-10-02 Dsm Sinochem Pharmaceuticals Netherlands B.V. Amine salts of pitavastatin and rosuvastatin

Also Published As

Publication number Publication date
CN101208307A (en) 2008-06-25
CN102807530B (en) 2015-08-05
JP2008546730A (en) 2008-12-25
AU2006261087A1 (en) 2006-12-28
EP1912952A1 (en) 2008-04-23
CN101208307B (en) 2012-10-17
EP2508514B1 (en) 2017-10-18
EP2508514A1 (en) 2012-10-10
IL187483A0 (en) 2008-02-09
EP1912952B1 (en) 2014-10-15
AU2006261087B2 (en) 2010-09-30
CN102807530A (en) 2012-12-05
IL187483A (en) 2014-08-31
US20090111839A1 (en) 2009-04-30
CA2612587C (en) 2013-02-19
JP5146965B2 (en) 2013-02-20
US9150518B2 (en) 2015-10-06
CA2612587A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
US9150518B2 (en) Process for preparing amorphous rosuvastatin calcium of impurities
EP1915349B2 (en) Process for preparing pure amorphous rosuvastatin calcium
JP2008044948A (en) Process for manufacturing calcium salt of rosuvastatin(e)-7-[4-(4-fluorophenyl)-6-iosopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6-enoic acid and crystalline intermediate thereof
EP2013188B1 (en) Rosuvastatin zinc salt
WO2007000121A1 (en) A method for the production of the hemi-calcium salt of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid
US9133132B2 (en) Method for the preparation of high-purity pharmaceutical intermediates
WO2012176218A1 (en) Process for preparing rosuvastatin calcium through novel amine salt
EP2646419B1 (en) Method for preparing rosuvastatin salts
WO2007086559A1 (en) Method for producing tetrahydropyran compound
JP2002069062A (en) Method for producing 3-hydroxyisoxazole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006754501

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 187483

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 9216/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2612587

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11922532

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006261087

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008517413

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200680022852.4

Country of ref document: CN

Ref document number: 5942/CHENP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006261087

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006261087

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006754501

Country of ref document: EP